RALEIGH, NC--(Marketwire - Dec 6, 2011) - InoLife Technologies, Inc. (OTCBB: [ INOL ]), a service based healthcare products development, integration and marketing company, announced today that Bob Haley has joined the company's executive team as Chief Operations Officer (COO). Haley brings forty-plus years of experience and a proven track record of success to InoLife Technologies.

As COO, Haley will lead and manage operational functions for InoLife Technologies. "Bob's experience working with rapid expansion, M&A and public offerings are just a few of the reasons we've chosen to hand him the operational reigns," said Gary Berthold, CEO of InoLife. Prior to joining InoLife Technologies, Inc., Haley was the CEO of Florida Medical Center part of the publicly traded company Tenet Healthcare.

About InoLife Technologies, Inc.
InoLife Technologies, Inc. is organized to develop and market DNA Testing products within the US. The Company's mission is to aggressively identify, manufacture and market innovative and affordable healthcare products and services directly to the marketplace. By targeting cutting-edge DNA-based testing and reporting methodologies, the company is able to significantly benefit the health and wellness needs of both individuals and their healthcare providers.

InoLife Technologies, Inc. markets the commercial use of proprietary Intellectual Property by manufacturing, brand marketing and selling an integrated program of age reversing creams and lotions. These products will be sold directly to consumers through e-commerce, direct sales, pharmacies, retailers, distributors and healthcare providers. It also offers products that are sold only to physicians, hospitals, outpatient facilities and others in the medical community for use with their patients.

Forward-Looking Statements: Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements including, but not limited to, certain delays beyond the Company's control with respect to market acceptance of new technologies, products and services, delays in testing and evaluation of products and services, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.